Seattle Genetics reveals positive data from tisotumab vedotin trial
Category: #health  By Pankaj Singh  Date: 2020-06-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Seattle Genetics reveals positive data from tisotumab vedotin trial

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing tisotumab vedotin for the treatment of patients with relapsed, progressed on or prior treated recurrent/metastatic cervical cancer.

For the record, Tisotumab vedotin is an investigational ADC (antibody-drug conjugate) directed to tissue factor and is being developed by Seattle Genetics, along with Genmab. Results from the trial showed a 24% confirmed ORR (objective response rate) by independent central review with a median duration of response (DOR) of 8.3 months.

Commenting on the trial, Roger Dansey, M.D., Chief Medical Officer, Seattle Genetics, said that first line chemotherapy currently available for recurrent or metastatic cervical cancer are limited, and indicate an unmet need for new treatment options.

Tisotumab vedotin has revealed clinically significant and durable objective responses with a manageable safety profile, and their firm is looking forward to discussing the potential submission of a Biologics License Application with the FDA to support an accelerated approval, said Dansey.

Estimates claim that, in 2020, over 13,500 women may be diagnosed with cervical cancer in the U.S., with around 4,200 projected deaths. Cervical cancer continues to be one of the leading causes of cancer related deaths in women globally, with over 311,000 fatalities annually.

Thanks to human papillomavirus (HPV) vaccine and routine medical examinations, incidences of cervical cancer have lowered substantially across developed economies. However, women are still diagnosed with cervical cancer, which often resurfaces or becomes metastatic.

Sources claim that additional tisotumab vedotin clinical trials are enrolling patients, including combination use of carboplatin, pembrolizumab, or bevacizumab, with a weekly dosing schedule in patients with locally advanced/metastatic cervical cancer. Apart from this, tisotumab vedotin is also being studied in other tissue factors that express tumor types like ovarian and other solid tumors.

Source Credit: https://www.businesswire.com/news/home/20200629005802/en/Seattle-Genetics-Announces-Positive-Topline-Results-Phase



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...